XORTX Therapeutics Correlations
XRTX Stock | USD 1.27 0.06 4.96% |
The current 90-days correlation between XORTX Therapeutics and Tff Pharmaceuticals is 0.13 (i.e., Average diversification). The correlation of XORTX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
XORTX Therapeutics Correlation With Market
Significant diversification
The correlation between XORTX Therapeutics and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding XORTX Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
XORTX |
Moving together with XORTX Stock
0.74 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
0.7 | LLY | Eli Lilly | PairCorr |
0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.72 | RDY | Dr Reddys Laboratories | PairCorr |
0.7 | TAK | Takeda Pharmaceutical | PairCorr |
0.63 | AMGN | Amgen Inc | PairCorr |
0.68 | ANRO | Alto Neuroscience, | PairCorr |
Moving against XORTX Stock
0.69 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
0.68 | GILD | Gilead Sciences | PairCorr |
0.62 | BHC | Bausch Health Companies | PairCorr |
0.59 | EWTX | Edgewise Therapeutics | PairCorr |
0.58 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
0.51 | WAT | Waters | PairCorr |
0.5 | VTRS | Viatris | PairCorr |
0.5 | BFRIW | Biofrontera Warrants | PairCorr |
0.41 | EBS | Emergent Biosolutions | PairCorr |
0.33 | GANX | Gain Therapeutics | PairCorr |
0.62 | BSX | Boston Scientific Corp Sell-off Trend | PairCorr |
0.49 | CPRX | Catalyst Pharmaceuticals | PairCorr |
0.45 | MNMD | Mind Medicine | PairCorr |
0.45 | DXCM | DexCom Inc Sell-off Trend | PairCorr |
0.32 | ABT | Abbott Laboratories Sell-off Trend | PairCorr |
Related Correlations Analysis
0.59 | 0.55 | 0.1 | -0.05 | TFFP | ||
0.59 | 0.36 | -0.62 | -0.34 | ELYM | ||
0.55 | 0.36 | 0.12 | -0.12 | INBX | ||
0.1 | -0.62 | 0.12 | 0.21 | ELVN | ||
-0.05 | -0.34 | -0.12 | 0.21 | MOLN | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between XORTX Stock performing well and XORTX Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze XORTX Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TFFP | 7.01 | (1.58) | 0.00 | (1.10) | 0.00 | 11.28 | 95.77 | |||
ELYM | 3.87 | (0.72) | 0.00 | 0.69 | 0.00 | 6.21 | 34.87 | |||
INBX | 2.31 | 0.09 | 0.02 | 0.26 | 2.72 | 5.54 | 16.80 | |||
ELVN | 2.01 | 0.03 | 0.01 | 0.16 | 2.18 | 5.84 | 12.96 | |||
MOLN | 4.43 | (0.08) | (0.01) | 0.07 | 4.92 | 9.38 | 52.92 |
XORTX Therapeutics Corporate Management
MD MBA | Chief Officer | Profile | |
Charlotte May | Corporate Secretary | Profile | |
MRCP MD | Chief Officer | Profile | |
David MacDonald | Consultant Operations | Profile | |
Nick Rigopoulos | Director Communications | Profile | |
Allen Davidoff | CEO, Founder | Profile |